Vitro Biopharma Advances Commercialization of its Fertility Drugs: Licensing Partner to Seek Registration in International Markets

Golden, Colorado—August 28, 2012—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in the commercialization of its infertility treatment drug, Vitropin™, a highly purified form of FSH produced through Vitro Biopharma’s patented production process. During 2011, Vitro licensed two of its patents and certain rights to other related intellectual property to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies (ART). Dr. Posillico and his team of professionals have recently begun the process of registration of Vitropin™ and related products in